IL191117A - Use of an anti-40 cd antibody in the preparation of a pharmaceutical preparation for the treatment of inflammatory or autoimmune disease and a preparation prepared therefor - Google Patents

Use of an anti-40 cd antibody in the preparation of a pharmaceutical preparation for the treatment of inflammatory or autoimmune disease and a preparation prepared therefor

Info

Publication number
IL191117A
IL191117A IL191117A IL19111708A IL191117A IL 191117 A IL191117 A IL 191117A IL 191117 A IL191117 A IL 191117A IL 19111708 A IL19111708 A IL 19111708A IL 191117 A IL191117 A IL 191117A
Authority
IL
Israel
Prior art keywords
antibody
preparation
treatment
pharmaceutical composition
disease
Prior art date
Application number
IL191117A
Other languages
English (en)
Hebrew (he)
Other versions
IL191117A0 (en
Original Assignee
Novartis Ag
Xoma Technology Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag, Xoma Technology Ltd filed Critical Novartis Ag
Publication of IL191117A0 publication Critical patent/IL191117A0/en
Publication of IL191117A publication Critical patent/IL191117A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2887—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Diabetes (AREA)
  • Neurology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Hematology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Ophthalmology & Optometry (AREA)
  • Transplantation (AREA)
  • Emergency Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Dermatology (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
IL191117A 2005-11-01 2008-04-28 Use of an anti-40 cd antibody in the preparation of a pharmaceutical preparation for the treatment of inflammatory or autoimmune disease and a preparation prepared therefor IL191117A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US73258005P 2005-11-01 2005-11-01
PCT/US2006/042601 WO2007053661A2 (en) 2005-11-01 2006-11-01 Uses of anti-cd40 antibodies

Publications (2)

Publication Number Publication Date
IL191117A0 IL191117A0 (en) 2008-12-29
IL191117A true IL191117A (en) 2013-05-30

Family

ID=38006484

Family Applications (1)

Application Number Title Priority Date Filing Date
IL191117A IL191117A (en) 2005-11-01 2008-04-28 Use of an anti-40 cd antibody in the preparation of a pharmaceutical preparation for the treatment of inflammatory or autoimmune disease and a preparation prepared therefor

Country Status (12)

Country Link
US (1) US20090202531A1 (enExample)
EP (1) EP1957538B1 (enExample)
JP (1) JP2009513712A (enExample)
KR (1) KR101395005B1 (enExample)
CN (1) CN101351478A (enExample)
AU (1) AU2006308860B2 (enExample)
BR (1) BRPI0618217A2 (enExample)
CA (1) CA2627891A1 (enExample)
ES (1) ES2428089T3 (enExample)
IL (1) IL191117A (enExample)
RU (1) RU2442606C2 (enExample)
WO (1) WO2007053661A2 (enExample)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10303974A1 (de) 2003-01-31 2004-08-05 Abbott Gmbh & Co. Kg Amyloid-β(1-42)-Oligomere, Verfahren zu deren Herstellung und deren Verwendung
AU2006308606C1 (en) 2005-11-01 2013-07-25 Novartis Ag Uses of anti-CD40 antibodies
KR20080090408A (ko) 2005-11-30 2008-10-08 아보트 러보러터리즈 항-Ａβ 글로불로머 항체, 이의 항원-결합 잔기, 상응하는하이브리도마, 핵산, 벡터, 숙주 세포, 당해 항체의 제조방법, 당해 항체를 포함하는 조성물, 당해 항체의 용도 및당해 항체의 사용 방법
SG10201706600VA (en) 2005-11-30 2017-09-28 Abbvie Inc Monoclonal antibodies and uses thereof
US8455626B2 (en) 2006-11-30 2013-06-04 Abbott Laboratories Aβ conformer selective anti-aβ globulomer monoclonal antibodies
WO2008104386A2 (en) 2007-02-27 2008-09-04 Abbott Gmbh & Co. Kg Method for the treatment of amyloidoses
EP2077281A1 (en) * 2008-01-02 2009-07-08 Bergen Teknologioverforing AS Anti-CD20 antibodies or fragments thereof for the treatment of chronic fatigue syndrome
JP5828151B6 (ja) 2009-01-06 2018-09-19 アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル アテローム性動脈硬化の処置のためのｂ細胞枯渇剤
CA2767616A1 (en) 2009-07-09 2011-01-13 The Scripps Research Institute Gene expression profiles associated with chronic allograft nephropathy
EP2558494B1 (en) 2010-04-15 2018-05-23 AbbVie Inc. Amyloid-beta binding proteins
RU2441023C1 (ru) * 2010-07-15 2012-01-27 Олег Ильич Эпштейн Лекарственное средство для лечения рассеянного склероза и способ лечения рассеянного склероза
RU2509573C2 (ru) * 2010-07-27 2014-03-20 Олег Ильич Эпштейн Лекарственное средство для лечения рассеянного склероза и способ лечения рассеянного склероза
US9062101B2 (en) 2010-08-14 2015-06-23 AbbVie Deutschland GmbH & Co. KG Amyloid-beta binding proteins
AR083847A1 (es) 2010-11-15 2013-03-27 Novartis Ag Variantes de fc (fragmento constante) silenciosas de los anticuerpos anti-cd40
WO2012075111A1 (en) 2010-11-30 2012-06-07 Novartis Ag Uses of anti-cd40 antibodies in combination therapy for b cell-related cancers
HUE065915T2 (hu) 2011-03-11 2024-06-28 Beth Israel Deaconess Medical Ct Inc Anti-CD40 antitestek és alkalmazásaik
CN103635488B (zh) 2011-04-29 2016-12-14 埃派斯进有限公司 抗-cd40抗体及其使用方法
CA2839542A1 (en) * 2011-06-17 2012-12-20 Constitution Medical, Inc. Fixative and staining solutions
US20140004131A1 (en) 2012-05-04 2014-01-02 Novartis Ag Antibody formulation
EP2914627B1 (en) 2012-10-30 2021-04-07 Apexigen, Inc. Anti-cd40 antibodies and methods of use
ES3040431T3 (en) 2014-03-12 2025-10-31 Yeda Res & Dev Reducing systemic regulatory t cell levels or activity for treatment of disease and injury of the cns
CN108025068A (zh) * 2014-03-12 2018-05-11 耶达研究与开发有限公司 降低系统性调节性t细胞水平或活性来治疗cns的疾病和损伤
US10618963B2 (en) 2014-03-12 2020-04-14 Yeda Research And Development Co. Ltd Reducing systemic regulatory T cell levels or activity for treatment of disease and injury of the CNS
US10519237B2 (en) 2014-03-12 2019-12-31 Yeda Research And Development Co. Ltd Reducing systemic regulatory T cell levels or activity for treatment of disease and injury of the CNS
US10443100B2 (en) 2014-05-22 2019-10-15 The Scripps Research Institute Gene expression profiles associated with sub-clinical kidney transplant rejection
US11104951B2 (en) 2014-05-22 2021-08-31 The Scripps Research Institute Molecular signatures for distinguishing liver transplant rejections or injuries
AU2015360502A1 (en) 2014-12-10 2017-06-29 Regents Of The University Of Minnesota Genetically modified cells, tissues, and organs for treating disease
UY36692A (es) 2015-05-29 2016-12-30 Abbvie Inc Anticuerpos anti-cd40 y usos de los mismos
EP3307322B1 (en) 2015-09-04 2021-02-17 Primatope Therapeutics Inc. Humanized anti-cd40 antibodies and uses thereof
MX2018003905A (es) * 2015-09-30 2018-09-06 Janssen Biotech Inc Anticuerpos agonistas que se unen específicamente a cd40 humana y métodos de uso.
BR112018076260A2 (pt) 2016-06-20 2019-03-26 Kymab Limited anticorpo ou fragmento do mesmo que se liga especificamente a hpd-l1, anticorpo biespecífico ou proteína de fusão, uso de um anticorpo ou fragmento, método, composição farmacêutica, método de modulação, método de inibição, método de tratamento, ácido nucleico, vetor, hospedeiro e imunocitocina
US11242397B2 (en) * 2017-06-01 2022-02-08 Pb Immune Therapeutics Inc. Anti-CD40 antibody and methods for blocking CD40-CD40L signaling
KR20210035805A (ko) 2018-06-15 2021-04-01 플래그쉽 파이어니어링 이노베이션스 브이, 인크. 세포후 신호전달 인자의 조절을 통한 면역 활성의 증가
MA55805A (fr) 2019-05-03 2022-03-09 Flagship Pioneering Innovations V Inc Métodes de modulation de l'activité immunitaire
US20230114107A1 (en) 2019-12-17 2023-04-13 Flagship Pioneering Innovations V, Inc. Combination anti-cancer therapies with inducers of iron-dependent cellular disassembly
US20230355804A1 (en) 2020-06-29 2023-11-09 Flagship Pioneering Innovations V, Inc. Viruses engineered to promote thanotransmission and their use in treating cancer
WO2022120038A1 (en) * 2020-12-02 2022-06-09 Albert Einstein College Of Medicine Method for predicting patient response to cd40-targeted therapies
CA3214085A1 (en) 2021-03-31 2022-10-06 Darby Rye Schmidt Thanotransmission polypeptides and their use in treating cancer
KR20240026507A (ko) 2021-06-29 2024-02-28 플래그쉽 파이어니어링 이노베이션스 브이, 인크. 타노트랜스미션을 촉진시키도록 엔지니어링된 면역 세포 및 이의 용도
US20240343817A1 (en) * 2021-07-14 2024-10-17 Staidson (Beijing) Biopharmaceuticals Co., Ltd. Antibody that specifically recognizes cd40 and application thereof
US12234294B2 (en) 2021-11-05 2025-02-25 Kiniksa Pharmaceuticals, Gmbh Pharmaceutical composition of a humanized anti-CD40 antibody
WO2024077191A1 (en) 2022-10-05 2024-04-11 Flagship Pioneering Innovations V, Inc. Nucleic acid molecules encoding trif and additionalpolypeptides and their use in treating cancer
WO2024151687A1 (en) 2023-01-09 2024-07-18 Flagship Pioneering Innovations V, Inc. Genetic switches and their use in treating cancer

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6136310A (en) * 1991-07-25 2000-10-24 Idec Pharmaceuticals Corporation Recombinant anti-CD4 antibodies for human therapy
US5874082A (en) * 1992-07-09 1999-02-23 Chiron Corporation Humanized anti-CD40 monoclonal antibodies and fragments capable of blocking B cell proliferation
JP3675819B2 (ja) * 1993-10-01 2005-07-27 イミュネックス・コーポレーション Ｃｄ４０に対する抗体
US6946129B1 (en) * 1999-06-08 2005-09-20 Seattle Genetics, Inc. Recombinant anti-CD40 antibody and uses thereof
US7063845B2 (en) * 2000-04-28 2006-06-20 Gemini Science, Inc. Human anti-CD40 antibodies
US7858300B2 (en) * 2001-10-19 2010-12-28 Centre Hospitalier Regional Et Universitaire De Tours Methods and compositions to evaluate antibody treatment response
HRP20090325T1 (en) * 2003-04-09 2009-07-31 Genentech Therapy of autoimmune disease in a patient with an inadequate response to a tnf-alpha inhibitor
RS53073B (sr) * 2003-11-04 2014-04-30 Novartis Vaccines And Diagnostics Inc. Upotreba antagonističkih anti-cd40 monoklonska antitela
SI1682177T1 (sl) * 2003-11-04 2010-12-31 Novartis Vaccines & Diagnostic Uporaba antagonističnih anti-CD40 protiteles za zdravljenje kronične limfocitne levkemije
DK1684805T3 (da) * 2003-11-04 2010-10-04 Novartis Vaccines & Diagnostic Anvendelse af antagonist anti-CD40-monoklonale antistoffer til behandling af multipel myeloma
PT1684869E (pt) * 2003-11-04 2011-09-16 Novartis Vaccines & Diagnostic Métodos de terapêutica para cancros relacionados com células b
EP2301575A1 (en) * 2003-11-04 2011-03-30 Novartis Vaccines and Diagnostics, Inc. Methods of therapy for solid tumors expressing the CD40 cell-surface antigen
US20070231813A1 (en) * 2004-06-01 2007-10-04 Centre Hospitalier Regional Et Universitaire De Tours Fcgr3a Gebotype and Methods for Evaluating Treatment Response to Non-Depleting Antibodies
US20080057070A1 (en) * 2004-11-04 2008-03-06 Chiron Corporation Antagonist Anti-Cd40 Monoclonal Antibodies and Methods for Their Use

Also Published As

Publication number Publication date
CA2627891A1 (en) 2007-05-10
AU2006308860A1 (en) 2007-05-10
AU2006308860B2 (en) 2012-01-12
ES2428089T3 (es) 2013-11-05
BRPI0618217A2 (pt) 2011-08-23
RU2008121899A (ru) 2009-12-10
HK1122579A1 (en) 2009-05-22
EP1957538B1 (en) 2013-05-22
RU2442606C2 (ru) 2012-02-20
WO2007053661A3 (en) 2007-11-01
KR20080100806A (ko) 2008-11-19
EP1957538A2 (en) 2008-08-20
US20090202531A1 (en) 2009-08-13
IL191117A0 (en) 2008-12-29
JP2009513712A (ja) 2009-04-02
WO2007053661A2 (en) 2007-05-10
KR101395005B1 (ko) 2014-05-21
CN101351478A (zh) 2009-01-21

Similar Documents

Publication Publication Date Title
IL191117A (en) Use of an anti-40 cd antibody in the preparation of a pharmaceutical preparation for the treatment of inflammatory or autoimmune disease and a preparation prepared therefor
EP2023955A4 (en) Administration of anti-CD3 antibodies in the treatment of autoimmune diseases
IL185483A (en) Composition of anti-4-ctla antibody and their use in the preparation of anti-neoplastic drugs
IL198870A0 (en) ANTIBODIES THAT BIND TO HUMAN PDGFRa AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME
SG10201608268RA (en) Human antibodies that bind cxcr4 and uses thereof
IL185462A0 (en) New pharmaceutical compositions useful in the treatment of pain
GB0412753D0 (en) Pharmaceutical compositions for the treatment of disease and/or symptoms in arthritis
IL199045A0 (en) Antagonist anti-notch3 antibodies and their use in the prevention and treatment of notch3-related diseases
IL200572A0 (en) Antagonist ox40 antibodies and their use in the treatment of inflammatory and autoimmune diseases
IL188732A (en) Use of ibuprofen and pamotidine for drug preparation
HUS1800034I1 (hu) Anti-FGF23 ellenanyag és anti-FGF23 ellenanyagot tartalmazó gyógyászati készítmény
ZA200902419B (en) Anti-notch3 agonist antibodies and their use in the treatment of notch3-related diseases
EP1890677A4 (en) PHARMACEUTICAL COMPOSITIONS AND THEIR USE
IL185723A0 (en) Controlled release pharmaceutical compositions of liothyronine and methods of making and using the same
IL211904A (en) Kit and preparations containing methotrexate and anti-cd4 antibody for the treatment of rheumatic disease
IL178067A0 (en) Pharmaceutical dosage forms and compositions
ZA200702038B (en) Pharmaceutical composition drospirenone and ethynyle-stradiol
WO2006020430A8 (en) Novel composition and methods for the treatment of immune related disease
ZA200904382B (en) Antagonist anti-Notch3 antibodies and their use in the prevention and treatment of Notch3-retaled diseases
ZA200609585B (en) Compositions comprising glycosaminoglycan and non steriodal anti-inflammatory drug
GB0406014D0 (en) Pharmaceutical composition and use
HK1134300A (en) Antagonist anti-notch3 antibodies and their use in the prevention and treatment of notch3-related diseases
HK1134301A (en) Anti-notch3 agonist antibodies and their use in the treatment of notch3-related diseases
IL198079A0 (en) Anti-notch3 agonist antibodies and their use in the treatment of notch3-related diseases
HK1110217A (en) New pharmaceutical compositions useful in the treatment of pain

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed
MM9K Patent not in force due to non-payment of renewal fees